Connect with us

Public Companies

Small Pharma Expands IP With Another US Patent

The article Small Pharma Expands IP With Another US Patent was originally published on Microdose.

With the recent focus (and fuss) around patent protection…

Published

on

The article Small Pharma Expands IP With Another US Patent was originally published on Microdose.

With the recent focus (and fuss) around patent protection and psychedelic IP, Small Pharma seems to be quietly building a secure IP strategy around their lead candidate compound.

This latest patent marks the company’s twelfth granted patent in its psychedelic and non-psychedelic portfolio, which includes over 70 pending applications. See the full press release below.

For more on Small Pharma, check out Small Pharma Completes Enrollment in Phase IIa DMT Trial and Small Pharma Granted U.S. Patent for Injectable DMT.

 

 

Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio

Brings total to twelve granted patents across the Company’s full portfolio

 

LONDON, Oct. 19, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that as of October 18, 2022, it has been granted patent no. 11,471,417 by the United States Patent Office. This United States patent provides protection for a therapeutic composition of a small group of deuterated N,N-dimethyltryptamine (“DMT”) compounds, with expected lifetime of exclusivity until April 2041, further strengthening the Company’s intellectual property (“IP”) position in support of its research and development.

This patent sits alongside Small Pharma’s existing European granted patent no. 3902541, providing additional protection for the Company’s deuterated pipeline in a core market. The grant marks the Company’s twelfth granted patent in its psychedelic and non-psychedelic portfolio, which includes over 70 pending applications, and is the second United States patent grant within its psychedelic portfolio.

George Tziras, Chief Executive Officer of Small Pharma, said: “We have made significant strides this year progressing our research and development programs and in securing key IP to support and protect them. We secured eight patent grants so far this year, bringing our total from four to twelve. The grant of this second United States patent effectively protects all pharmaceutical formulations of the specified deuterated DMT compounds, enabling us to progress our deuterated pipeline with even greater confidence.”

About Small Pharma

Small Pharma is a biotechnology company progressing a pipeline of short-acting psychedelic assisted therapies for the treatment of mental health conditions. The Company’s current focus is on exploring new therapeutic approaches for depression. Small Pharma’s lead candidate, SPL026, is a proprietary synthetic formulation of DMT. The Company is advancing a clinical program of intravenous SPL026 with supportive therapy for the treatment of Major Depressive Disorder, which was granted an Innovation Passport designation from the U.K. Medicines and Healthcare products Regulatory Agency (“MHRA”). In addition, Small Pharma has a pipeline of proprietary preclinical assets in development.

Read More

Trending

 

NXTpsychedelics is part of NXT Financial Media Group. Copyright 2021 NXT.financial media